JUNIOR STRENGTH CHEWABLE ACETAMINOPHEN TABLETS USP 160MG 160 MG
ACETAMINOPHEN : 160 MG · DIN 02252821 · CELLCHEM PHARMACEUTICALS INC.
Health Canada status: APPROVED
What is JUNIOR STRENGTH CHEWABLE ACETAMINOPHEN TABLETS USP 160MG?
JUNIOR STRENGTH CHEWABLE ACETAMINOPHEN TABLETS USP 160MG 160 MG contains ACETAMINOPHEN : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02252821, held by CELLCHEM PHARMACEUTICALS INC., supplied as TABLET (CHEWABLE) for ORAL administration. Health Canada currently lists it as approved, status dated 14-Jan-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02252821 |
|---|---|
| Brand name | JUNIOR STRENGTH CHEWABLE ACETAMINOPHEN TABLETS USP 160MG |
| Generic / active ingredient | ACETAMINOPHEN : 160 MG |
| Manufacturer | CELLCHEM PHARMACEUTICALS INC. |
| Strength | 160 MG |
| Dosage form | TABLET (CHEWABLE) |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | N02BE01 ACETAMINOPHEN (PARACETAMOL) |
| AHFS class | 28:08.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 14-Jan-2020 |
Is ACETAMINOPHEN (PARACETAMOL) in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by APOTEX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for JUNIOR STRENGTH CHEWABLE ACETAMINOPHEN TABLETS USP 160MG
What can be used instead?
Other Canadian products sharing ATC code N02BE01 ACETAMINOPHEN (PARACETAMOL). 75 of 409 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACET 120 | 120 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230434 |
| ACET 160 | 160 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230435 |
| ACET 325 | 325 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230436 |
| ACET 650 | 650 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230437 |
| ACETAMINOPHEN 160 MG CHEWABLE TABLETS | 160 MG | TABLET (CHEWABLE) | LABORATOIRES TRIANON INC. | MARKETED | DIN 02237562 |
| ACETAMINOPHEN 325MG TABLETS REGULAR STRENGTH | 325 MG | TABLET | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02252805 |
| ACETAMINOPHEN 500 MG TABLETS EXTRA STRENGTH EASY TO SWALLOW | 500 MG | TABLET | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02255251 |
| ACETAMINOPHEN 500MG TABLETS EXTRA STRENGTH | 500 MG | TABLET | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02252813 |
| ACETAMINOPHEN ARTHRITIS PAIN | 650 MG | TABLET (EXTENDED-RELEASE) | PERRIGO INTERNATIONAL | MARKETED | DIN 02272482 |
| ACETAMINOPHEN CAPLETS 325 MG | 325 MG | TABLET | LABORATOIRES TRIANON INC. | MARKETED | DIN 01977415 |
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ask about availability of JUNIOR STRENGTH CHEWABLE ACETAMINOPHEN TABLETS USP 160MG
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.